Capital Fund Management (CFM)’s Genmab GMAB Stock Holding History

Capital Fund Management (CFM)’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$861K	Sell	31,361 -24,038	-43%	-$639K	﹤0.01%	1737
2026 Q1	$1.49M	Buy	+55,399	New	+$1.66M	0.01%	1509
2025 Q4	–	Sell	-161,676	Closed	-$4.96M	–	2480
2025 Q3	$4.96M	Sell	161,676 -64,908	-29%	-$1.58M	0.01%	1262
2025 Q2	$4.68M	Buy	226,584 +119,061	+111%	+$2.44M	0.01%	1180
2025 Q1	$2.11M	Buy	+107,523	New	+$2.26M	0.01%	1403
2024 Q4	–	Sell	-32,880	Closed	-$802K	–	2107
2024 Q3	$802K	Buy	32,880 +15,428	+88%	+$412K	﹤0.01%	1747
2024 Q2	$439K	Sell	17,452 -22,099	-56%	-$627K	﹤0.01%	1781
2024 Q1	$1.18M	Buy	+39,551	New	+$1.16M	﹤0.01%	1649
2022 Q3	–	Sell	-12,720	Closed	-$413K	–	1513
2022 Q2	$413K	Buy	+12,720	New	+$412K	﹤0.01%	1286

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Fund Management (CFM)'s GMAB Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Genmab (GMAB) stake by 43% in Q2 2026, selling an estimated $639K and leaving 31,361 shares worth $861K. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

Capital Fund Management (CFM) first reported a position in GMAB in Q2 2022 and has held it in 9 quarters since. The position peaked at $4.96M in Q3 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Capital Fund Management (CFM) held 31,361 shares of Genmab worth $861K as of Q2 2026.
Capital Fund Management (CFM) sold 24,038 Genmab shares in Q2 2026, an estimated $639K.
Genmab made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1737 holding.
Capital Fund Management (CFM) first reported a position in Genmab in Q2 2022 and has held it in 9 quarters since.
Capital Fund Management (CFM)'s Genmab position peaked at $4.96M in Q3 2025.
290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.